Last updated: February 9, 2026
VANDA PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. | 2:22-cv-07528
Case Overview:
Vanda Pharmaceuticals Inc. filed a patent infringement lawsuit against Teva Pharmaceuticals USA Inc. in the U.S. District Court for the Central District of California. The suit centers on patent rights related to Vanda’s medication, Viibryd (vilazodone HCl), a selective serotonin reuptake inhibitor used for depression. The complaint alleges that Teva’s generic versions infringe on Vanda’s patent, U.S. Patent No. 8,799,336, issued on August 12, 2014.
Litigation Timeline and Key Events:
- Filing Date: December 8, 2022
- Patent at Issue: U.S. Patent No. 8,799,336, titled "Methods of Treating Depression with Vilazodone"
- Teva’s ANDA Submission: Likely filed prior to complaint, seeking FDA approval to market a generic vilazodone product
- Preliminary Motions: As of the latest update, no major dispositive motions have been filed or decided
Claims and Allegations:
- Patent Infringement: Vanda alleges that Teva’s proposed generic infringes claims 1-20 of the ’336 patent, which cover methods of treating depression using vilazodone in specific dosing regimens
- Invalidity Claims: Vanda asserts that the patent is valid and enforceable, emphasizing the novelty and non-obviousness of their method claims as demonstrated in patent prosecution records
- Exclusive Rights: Vanda seeks injunctive relief and damages for alleged patent infringement, aiming to prevent Teva from marketing a generic version before patent expiration or a court ruling
Legal Strategies and Considerations:
- Infringement Challenge: Vanda is expected to provide expert testimony and patent construction analyses to establish claims’ scope and infringement
- Invalidity Defense Anticipation: Teva may counter with prior art references published before the patent’s priority date, or argue obviousness based on existing depression treatment methods
- Regulatory Aspects: The case could impact FDA approval and market entry timelines for Teva’s generic vilazodone, potentially leading to a stay or delay if patent issues are unresolved
Potential Outcomes and Impacts:
- Patent Validity: A finding of invalidity could allow Teva to proceed with commercialization
- Infringement Ruling: A ruling of infringement could lead to an injunction preventing Teva’s product launch, significant monetary damages, or both
- Settlement Possibility: Patent litigation often results in settlement agreements, licensing arrangements, or patent licenses to resolve disputes expediently
Comparative Context:
- Patent Litigation in Generic Drug Market: Patent disputes in the biologics and small molecule sectors involve similar patent claims, often focusing on method-of-use patents like the ’336
- Market Implications: A breach of patent rights can delay generic entry, affecting drug pricing and market competition
Current Status and Next Steps:
- No trial date has been set. The parties likely will engage in discovery over the next 12-24 months, including patent claim construction, fact and expert discovery.
- A settlement or a summary judgment motion could be scheduled before trial, depending on case development.
Key Takeaways
- The case revolves around patent rights for vilazodone and potential infringement by Teva’s generic product.
- The outcome hinges on patent validity and scope, with the court assessing both during litigation.
- Settlement remains a common resolution in such patent disputes, though injunctive relief and damages are possible if infringement is established.
- The case’s progression could influence generic drug entry for depression treatments in the U.S. market.
- Patent litigation timelines typically span 2-4 years, depending on procedural complexity and court docket.
FAQs
1. What is the basis for Vanda’s patent claim?
Vanda claims exclusive rights to method-of-treatment claims involving vilazodone for depression, specifically certain dosing regimens outlined in patent ’336.
2. How does Teva typically defend in patent infringement cases?
Teva may argue patent invalidity based on prior art or obviousness, contest infringement by challenging claim scope, or seek design-around options.
3. What are the potential consequences if Teva is found infringing?
If infringement is established, Teva could be ordered to cease sales, pay damages, or both. An injunction might delay or prevent Teva’s market entry.
4. How long does patent litigation generally last?
From filing through trial, patent disputes can take 2 to 4 years, depending on case complexity and procedural issues.
5. Why is patent litigation important in the pharmaceutical sector?
It determines rights to market exclusive drugs, impacting pricing, competition, and innovation, particularly as generic entry affects revenue streams.
References
[1] Court docket for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 2:22-cv-07528.
[2] U.S. Patent No. 8,799,336.
[3] FDA Drug Approval and Patent Data.
